Literature DB >> 17391445

Animal models for mucopolysaccharidosis disorders and their clinical relevance.

Mark E Haskins1.   

Abstract

UNLABELLED: Progress in understanding how a particular genotype produces the phenotype of an inborn error of metabolism, such as a mucopolysaccharidosis, in human patients has been facilitated by the study of animals with mutations in the orthologous genes. These are not just animal models, but true orthologues of the human genetic disease, with defects involving the same evolutionarily conserved genes and the same molecular, biochemical, and anatomic lesions as in human patients. These animals are often domestic species because of the individual medical attention paid to them, particularly dogs and cats. In addition, naturally occurring mouse models have also been found in breeding colonies. Within the last several decades, advances in molecular biology have allowed the production of knockout mouse models of human genetic disease, including the lysosomal storage diseases. The ability to use both inbred strains of a small, prolific species together with larger out-bred animals found because of their disease phenotype provides a powerful combination with which to investigate pathogenesis, develop approaches to therapy, and define biomarkers to evaluate therapeutic success. This has been true for the inborn errors of metabolism and, in particular, the mucopolysaccharidoses.
CONCLUSION: Animal models of human genetic disease continue to play an important role in understanding the molecular and physiological consequences of lysosomal storage diseases and to provide an opportunity to evaluate the efficacy and safety of therapeutic interventions.

Entities:  

Mesh:

Year:  2007        PMID: 17391445      PMCID: PMC3351033          DOI: 10.1111/j.1651-2227.2007.00211.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  93 in total

Review 1.  Bone marrow transplantation for genetic disorders.

Authors:  J A Brochstein
Journal:  Oncology (Williston Park)       Date:  1992-03       Impact factor: 2.990

Review 2.  Gene therapy of severe combined immunodeficiencies.

Authors:  M Cavazzana-Calvo; S Hacein-Bey; F Yates; J P de Villartay; F Le Deist; A Fischer
Journal:  J Gene Med       Date:  2001 May-Jun       Impact factor: 4.565

3.  Enzyme replacement therapy in feline mucopolysaccharidosis I.

Authors:  E D Kakkis; E Schuchman; X He; Q Wan; S Kania; S Wiemelt; C W Hasson; T O'Malley; M A Weil; G A Aguirre; D E Brown; M E Haskins
Journal:  Mol Genet Metab       Date:  2001-03       Impact factor: 4.797

4.  Clinical vignette. Mucopolysaccharidosis VI in a miniature pinscher.

Authors:  T M Neer; S M Dial; R Pechman; P Wang; J L Oliver; U Giger
Journal:  J Vet Intern Med       Date:  1995 Nov-Dec       Impact factor: 3.333

5.  Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase.

Authors:  Paul Harmatz; David Ketteridge; Roberto Giugliani; Natalie Guffon; Elisa Leão Teles; M Clara Sá Miranda; Zi-Fan Yu; Stuart J Swiedler; John J Hopwood
Journal:  Pediatrics       Date:  2005-06       Impact factor: 7.124

6.  Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I.

Authors:  E D Kakkis; M F McEntee; A Schmidtchen; E F Neufeld; D A Ward; R E Gompf; S Kania; C Bedolla; S L Chien; R M Shull
Journal:  Biochem Mol Med       Date:  1996-08

7.  Adeno-associated virus vector-mediated transduction in the cat brain.

Authors:  Charles H Vite; Marco A Passini; Mark E Haskins; John H Wolfe
Journal:  Gene Ther       Date:  2003-10       Impact factor: 5.250

8.  The Twitcher mouse: an enzymatically authentic model of human globoid cell leukodystrophy (Krabbe disease).

Authors:  T Kobayashi; T Yamanaka; J M Jacobs; F Teixeira; K Suzuki
Journal:  Brain Res       Date:  1980-12-08       Impact factor: 3.252

9.  N-acetylglucosamine 6-sulphatase deficiency in a Nubian goat: a model of Sanfilippo syndrome type D (mucopolysaccharidosis IIID).

Authors:  J N Thompson; M Z Jones; G Dawson; P S Huffman
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

10.  Syngeneic bone marrow transplantation reduces the hearing loss associated with murine mucopolysaccharidosis type VII.

Authors:  M S Sands; L C Erway; C Vogler; W S Sly; E H Birkenmeier
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

View more
  15 in total

1.  Delayed hypertrophic differentiation of epiphyseal chondrocytes contributes to failed secondary ossification in mucopolysaccharidosis VII dogs.

Authors:  Sun H Peck; Philip J M O'Donnell; Jennifer L Kang; Neil R Malhotra; George R Dodge; Maurizio Pacifici; Eileen M Shore; Mark E Haskins; Lachlan J Smith
Journal:  Mol Genet Metab       Date:  2015-09-26       Impact factor: 4.797

Review 2.  Clinical neurogenetics: neuropathic lysosomal storage disorders.

Authors:  Gregory M Pastores; Gustavo H B Maegawa
Journal:  Neurol Clin       Date:  2013-11       Impact factor: 3.806

3.  Altered olfactory epithelial structure and function in feline models of mucopolysaccharidoses I and VI.

Authors:  Fritz W Lischka; George Gomez; Karen K Yee; Luba Dankulich-Nagrudny; Leen Lo; Mark E Haskins; Nancy E Rawson
Journal:  J Comp Neurol       Date:  2008-11-20       Impact factor: 3.215

4.  Therapeutic approaches for lysosomal storage diseases.

Authors:  Gregory M Pastores
Journal:  Ther Adv Endocrinol Metab       Date:  2010-08       Impact factor: 3.565

5.  Mucopolysaccharidosis IIIB (Sanfilippo syndrome B) in a commercial emu (Dromaius novaehollandiae) flock.

Authors:  Seiche C Genger; Keijiro Mizukami; Michael P Martin; Jeffrey R Applegate; H John Barnes; Urs Giger
Journal:  Avian Pathol       Date:  2017-10-10       Impact factor: 3.378

6.  Assessment of bone dysplasia by micro-CT and glycosaminoglycan levels in mouse models for mucopolysaccharidosis type I, IIIA, IVA, and VII.

Authors:  Daniel J Rowan; Shunji Tomatsu; Jeffrey H Grubb; Adriana M Montaño; William S Sly
Journal:  J Inherit Metab Dis       Date:  2012-09-13       Impact factor: 4.982

Review 7.  Substrate deprivation therapy: a new hope for patients suffering from neuronopathic forms of inherited lysosomal storage diseases.

Authors:  Joanna Jakóbkiewicz-Banecka; Alicja Wegrzyn; Grzegorz Wegrzyn
Journal:  J Appl Genet       Date:  2007       Impact factor: 3.240

Review 8.  Pathogenesis and treatment of spine disease in the mucopolysaccharidoses.

Authors:  Sun H Peck; Margret L Casal; Neil R Malhotra; Can Ficicioglu; Lachlan J Smith
Journal:  Mol Genet Metab       Date:  2016-06-04       Impact factor: 4.797

9.  Excessive activity of cathepsin K is associated with cartilage defects in a zebrafish model of mucolipidosis II.

Authors:  Aaron C Petrey; Heather Flanagan-Steet; Steven Johnson; Xiang Fan; Mitche De la Rosa; Mark E Haskins; Alison V Nairn; Kelley W Moremen; Richard Steet
Journal:  Dis Model Mech       Date:  2011-11-01       Impact factor: 5.758

Review 10.  Neurobehavioral phenotypes of neuronopathic mucopolysaccharidoses.

Authors:  Rita Barone; Alessandra Pellico; Annarita Pittalà; Serena Gasperini
Journal:  Ital J Pediatr       Date:  2018-11-16       Impact factor: 2.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.